Atea’s AT-527, an oral antiviral drug candidate reduces viral replication in hospitalized patients with COVID-19 in phase 2 interim analysis
2021-06-30
Dear Investor,
Please find attached a press release from our partner Atea Pharmaceuticals:
https://ir.ateapharma.com/news-releases/news-release-details/ateas-527-oral-antiviral-drug-candidate-reduces-viral
Do not hesitate to contact us for any further questions.
With best regards,
| Roche Investor Relations | |
| Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com | Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: jon_kaspar.bayard@roche.com |
| Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com | Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com |
| Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com | Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com |
| Investor Relations North America | |
| Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
Investors
Investor updates
stay updated
get the latest news and updates to your inbox.